Turgay Ulaş

ORCID: 0000-0001-9332-663X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lymphoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Peptidase Inhibition and Analysis
  • Platelet Disorders and Treatments
  • Cutaneous lymphoproliferative disorders research
  • Chronic Lymphocytic Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • Blood groups and transfusion
  • Complement system in diseases
  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Eosinophilic Esophagitis
  • Gout, Hyperuricemia, Uric Acid
  • Helicobacter pylori-related gastroenterology studies
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Congenital Anomalies and Fetal Surgery
  • CAR-T cell therapy research
  • Venous Thromboembolism Diagnosis and Management
  • COVID-19 Clinical Research Studies
  • Parasitic infections in humans and animals
  • Acute Myocardial Infarction Research
  • Immunodeficiency and Autoimmune Disorders
  • Liver Disease and Transplantation
  • Inflammasome and immune disorders
  • Bacterial Identification and Susceptibility Testing

Ankara Onkoloji Eğitim ve Araştırma Hastanesi
2011-2024

Sağlık Bilimleri Üniversitesi
2024

Ministry of Health
2024

Near East University
2018-2023

Mersin Üniversitesi
2023

Akdeniz University
2014-2022

State Hospital
2012-2020

Marmara University
2020

Harran University
2011-2015

Gaziantep University
2014

Background and Aim: Breast cancer is the most common type of amongst women today. The aim this study was to examine association between complementary alternative medicine (CAM) quality life (QoL), anxiety depression demographic characteristics with breast cancer. Materials Methods: QoL measured by European Organization for Treatment Research Cancer core questionnaire (QLQ-C30, version 3.0) hospital scale. Results: In total, 122 patients were enrolled in 50% (n = 61) them reported that they...

10.4103/0973-1482.138010 article EN Journal of Cancer Research and Therapeutics 2014-01-01

Resistive index (RI) is an indirect measurement of blood flow resistance that can be used to evaluate vascular damage.The purpose this study the association between RI values orbital and intrarenal arteries by means Doppler ultrasonography (US).We evaluated 103 diabetic patients. As a control group, 30 subjects were examined. The patients divided into two groups. Group 1 consisted with urinary albumin excretion (UAE) <300 mg/day estimated glomerular filtration rate (eGFR) levels >90 ml/min...

10.1159/000336105 article EN Kidney & Blood Pressure Research 2012-01-01

The objective of the study was to examine quality life amongst end stage renal disease (ESRD) haemodialysis patients in Malaysia.A cross sectional descriptive conducted on 72 ESRD at a Dialysis Centre Malaysia. modified KDQOL-SF™ subscales, kidney disease-targeted scale and 36 item health survey questionnaires were used.The overall rating 66.73 ± 11.670 indicating good life. There no significant difference between for different domains according gender (p >0.05). However, there differences...

10.7417/ct.2013.1627 article EN PubMed 2013-01-01

Objective: In this experimental study, we investigated the possible effects of intracameral moxifloxacin on oxidative stress parameters and endothelial cell morphology in corneal tissue.Methods: total, 30 rats were randomly assigned to three groups 10 rats: sham group (Group 1, n = 10); control 2), where balanced salt solution (BSS) was administered at a dose 0.01 cc (n treatment 3), 0.05 mg/0.01 10). Total antioxidant status (TAS) total oxidant (TOS) tissue blood samples measured index...

10.3109/15569527.2014.918138 article EN Cutaneous and Ocular Toxicology 2014-06-25

A multicenter, retrospective, observational study was conducted to explore effectiveness and safety of ixazomib plus lenalidomide with dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM) patients following at least ≥ two lines therapy. Patients' treatment responses, overall response rate, progression-free survival adverse events were recorded. Mean age 54 66.5 ± 9.1 years. There 20 (37.0%) progression. Median 13 months who received a median three therapy 7.5-month follow-up...

10.1080/1120009x.2023.2208439 article EN Journal of Chemotherapy 2023-05-21

The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, the survival patients treated with BvB combination. In multi-centre real-life study, 61 HL received intravenous doses of 1.8 mg/kg Bv on first day plus 90 mg/m2 B second days 21-day cycle second-line...

10.1080/1120009x.2021.1976912 article EN Journal of Chemotherapy 2021-09-13

RS3PE (remitting seronegative, symmetric synovitis with pitting edema) is a benign, seronegative syndrome, an acute onset of edema on the dorsum both hands and feet, which affects predominantly peripheral joints such as wrists ankles symmetrically. A 58-year-old man presented symmetrical polysynovitis associated feet. He responded well to low-dose corticosteroids. There was no evidence erosion radiologically. The clinical manifestations patient were consistent syndrome. Here, we present case...

10.5152/tjr.2010.08 article EN cc-by-nc Turkish Journal of Rheumatology 2010-05-07

We investigated the effect of intravenous levosimendan on QT dispersion compared with dobutamine in patients acute decompensated heart failure.This prospective cohort study included 38 who were admitted failure (New York Heart Association functional class III-IV). Twenty-five (11 men, 14 women; mean age 70.5 ± 11.13 years) treated infusion and 13 (5 8 71.08 6.86 infusion. Intravenous was administered an initial bolus dose 12 μg/kg for 10 min, followed by a continuous 0.1 μg/kg/min 1 hour 23...

10.5152/akd.2012.004 article EN cc-by-nc Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology 2012-01-01
Coming Soon ...